AMRX Stock Analysis: Amneal Pharmaceuticals | NASDAQ
Drug Manufacturers - Specialty & Generic | NASDAQ, USA | Market Cap: 6.297m USD | 12M Return: 85.6% | US03168L1052 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 26.6M
EPS Trend: 72.5%
Qual. Beats: 0
Rev. Trend: 98.8%
Qual. Beats: 1
Warnings
No concerns identified
Tailwinds
Seasonality 11.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Amneal Pharmaceuticals, Inc. (AMRX) is a global biopharmaceutical company that develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products across the United States, India, Ireland, and other international markets. Founded in 2002 and headquartered in Bridgewater, New Jersey, the company operates through three reporting segments: Affordable Medicines, Specialty, and AvKARE. The Affordable Medicines segment covers a broad range of dosage forms, including oral solids, sterile injectables, inhalation products, ophthalmics, transdermal patches, and biosimilars. The Specialty segment focuses on central nervous system and endocrine disorders, with key branded products such as Rytary, CREXONT, and Unithroid/ONGENTYS targeting Parkinsons disease and hypothyroidism. The AvKARE segment supplies pharmaceuticals, medical, and surgical products primarily to U.S. government agencies, including the Department of Defense and the Department of Veterans Affairs, and distributes products under the AvKARE and AvPAK labels.
The companys products reach patients and institutions through multiple channels, including wholesalers, distributors, retail pharmacies, managed care organizations, purchasing co-ops, hospitals, and government agencies. The pharmaceutical industry in which Amneal operates is characterized by long product development timelines, heavy regulatory oversight from agencies such as the U.S. Food and Drug Administration, and significant revenue exposure to patent expirations and generic competition, which is a central feature of Amneals Affordable Medicines segment.
- CREXONT Parkinsons drug launch drives Specialty segment revenue growth
- Generic drug pricing pressure weighs on Affordable Medicines margins
- AvKARE government contracts expand with DoD and VA demand
| Net Income: 157.4m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.02 > 0.02 and ΔFCF/TA -5.47 > 1.0 |
| NWC/Revenue: 34.12% < 20% (prev 16.74%; Δ 17.39% < -1%) |
| CFO/TA 0.05 > 3% & CFO 200.8m > Net Income 157.4m |
| Net Debt (2.79b) to EBITDA (652.2m): 4.27 < 3 |
| Current Ratio: 2.20 > 1.5 & < 3 |
| Outstanding Shares: last quarter (328.1m) vs 12m ago 1.78% < -2% |
| Gross Margin: 39.32% > 18% (prev 37.67%; Δ 1.65% > 0.5%) |
| Asset Turnover: 86.61% > 50% (prev 83.35%; Δ 3.26% > 0%) |
| Interest Coverage Ratio: 2.01 > 6 (EBIT TTM 457.9m / Interest Expense TTM 227.5m) |
| A: 0.28 (Total Current Assets 1.95b - Total Current Liabilities 883.2m) / Total Assets 3.78b |
| B: -0.11 (Retained Earnings -415.1m / Total Assets 3.78b) |
| C: 0.13 (EBIT TTM 457.9m / Avg Total Assets 3.60b) |
| D: 0.01 (Book Value of Equity 33.0m / Total Liabilities 3.66b) |
| Altman-Z'' = 2.35 = BBB |
| DSRI: 1.10 (Receivables 1.02b/849.3m, Revenue 3.12b/2.85b) |
| GMI: 0.96 (GM 37.67% / 39.32%) |
| AQI: 0.89 (AQ_t 0.33 / AQ_t-1 0.38) |
| SGI: 1.09 (Revenue 3.12b / 2.85b) |
| TATA: -0.01 (NI 157.4m - CFO 200.8m) / TA 3.78b) |
| Beneish M = -2.98 (Cap -4..+1) = A |
As of September 18, 2026, the stock is trading at USD 18.08 with a total of 5,124,041 shares traded. Over the past week, the price has changed by +4.81%, over one month by -1.85%, over three months by +11.26% and over the past year by +85.63%.
Current recommended Stop Loss: 17.00 (which is 6% or 2.1 ATR below the current price).
Amneal Pharmaceuticals has received a consensus analysts rating of 4.25. Therefore, it is recommended to buy AMRX.
- StrongBuy: 1
- Buy: 3
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 21.3 | 18% |
P/E Trailing = 34.7692
P/E Forward = 6.2972
P/S = 2.0199
P/B = 175.6035
Revenue TTM = 3.12b USD
EBIT TTM = 457.9m USD
EBITDA TTM = 652.2m USD
Long Term Debt = 2.56b USD (from longTermDebt, last quarter)
Short Term Debt = 121.4m USD (from shortTermDebt, last quarter)
Debt = 2.91b USD (from shortLongTermDebtTotal, last quarter) + Leases 121.5m
Net Debt = 2.79b USD (calculated: Debt 2.91b - CCE 127.6m)
Enterprise Value = 9.08b USD (6.30b + Debt 2.91b - CCE 127.6m)
Interest Coverage Ratio = 2.01 (Ebit TTM 457.9m / Interest Expense TTM 227.5m)
EV/FCF = 109.3x (Enterprise Value 9.08b / FCF TTM 83.1m)
FCF Yield = 0.91% (FCF TTM 83.1m / Enterprise Value 9.08b)
FCF Margin = 2.67% (FCF TTM 83.1m / Revenue TTM 3.12b)
Net Margin = 5.05% (Net Income TTM 157.4m / Revenue TTM 3.12b)
Gross Margin = 39.32% ((Revenue TTM 3.12b - Cost of Revenue TTM 1.89b) / Revenue TTM)
Gross Margin QoQ = 42.01% (prev 44.31%)
Tobins Q-Ratio = 2.41 (Enterprise Value 9.08b / Total Assets 3.78b)
Interest Expense / Debt = 7.81% (Interest Expense 227.5m / Debt 2.91b)
Taxrate = 1.94% (1.38m / 71.0m)
NOPAT = 449.0m (EBIT 457.9m * (1 - 1.94%))
Current Ratio = 2.20 (Total Current Assets 1.95b / Total Current Liabilities 883.2m)
Debt / Equity = 88.22 (Debt 2.91b / totalStockholderEquity, last quarter 33.0m)
Debt / EBITDA = 4.27 (Net Debt 2.79b / EBITDA 652.2m)
Debt / FCF = 33.52 (Net Debt 2.79b / FCF TTM 83.1m)
Total Stockholder Equity = -48.2m (last 4 quarters mean from totalStockholderEquity)
RoA = 4.37% (Net Income 157.4m / Total Assets 3.78b)
RoE = -326.8% (negative equity) (Net Income TTM 157.4m / Total Stockholder Equity -48.2m)
RoCE = 18.20% (EBIT 457.9m / Capital Employed (Equity -48.2m + L.T.Debt 2.56b))
RoIC = 15.55% (NOPAT 449.0m / Invested Capital 2.89b)
WACC = 7.04% (E(6.30b)/V(9.21b) * Re(6.75%) + D(2.91b)/V(9.21b) * Rd(7.81%) * (1-Tc(0.02)))
Discount Rate = 6.75% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 85.58 | Cagr: 2.96%
[DCF] Terminal Value 73.10% ; FCFF base≈154.9m ; Y1≈135.8m ; Y5≈109.7m
[DCF] Fair Price = N/A (negative equity: EV 1.76b - Net Debt 2.79b = -1.02b; debt exceeds intrinsic value)
EPS Correlation: 72.49 | EPS CAGR: 13.28% | SUE: 0.84 | # QB: 0
Revenue Correlation: 98.76 | Revenue CAGR: 10.67% | SUE: 1.21 | # QB: 1
EPS current Quarter (2026-09-30): EPS=0.23 | Chg30d=-0.89% | Revisions=-50% | Analysts=6
EPS current Year (2026-12-31): EPS=1.01 | Chg30d=+0.81% | Revisions=+50% | GrowthEPS=+22.1% | GrowthRev=+4.5%
EPS next Year (2027-12-31): EPS=1.17 | Chg30d=-0.71% | Revisions=+50% | GrowthEPS=+15.9% | GrowthRev=+9.0%
[Analyst] Revisions Ratio: +25% (up=6, down=3)